Loading annual review details
Phibro Animal Health Corporation (PAHC)FY2026 investor yearly review
Across FY2026, management framed momentum as an integration-and-execution story: Animal Health drove consistent sales gains, while Phibro Forward initiatives supported improved profitability. The year-end narrative balanced efficiency progress with working-capital strain and clearer regulatory uncertainty around Brazil virginiamycin.
Overall investor read
Momentum with execution-sensitive cash conversion
Management highlighted stronger year-long operating progress, but free cash flow stayed limited versus profits amid inventory builds.
Primary financial signal
Gross margin held near one-third despite mix shifts
Gross margin was supported by mix and price actions, with management later expecting it to be essentially flat into FY2027.
Primary call signal
FY2027 guidance prudently offsets Brazil uncertainty
Management assumed minimal Brazil virginiamycin contribution and reiterated regulatory timing could remain an upside/downside factor.
Headline results that summarize FY2026 business momentum and profitability/cash outcomes.
Revenue
Revenue grew 17.1% supported by Animal Health and MFA integration.
Gross margin
Management attributed margin strength to mix and price actions during FY2026.
Operating margin
Operating margin reflects improved profitability alongside higher SG&A investment.
Net income
Net income more than doubled year over year, per FY2026 reporting.
Diluted EPS
Diluted EPS rose to $2.44, supporting the year-end earnings narrative.
Operating cash flow
Operating cash flow declined 13.9% as inventory pressures weighed on conversion.
Free cash flow
Free cash flow fell to $9.87M, with management citing inventory build impact.
Net debt
Net debt stood at $727.35M at year end, with liquidity also strengthened.
FY2026 evolved from early integration optimism to a more operationally specific execution story—while working capital and Brazil regulatory timing became the primary year-end uncertainty.
Integration & commercial execution
From Q1 and Q2, management repeatedly linked growth to successfully integrating the acquired MFA portfolio, supported by disciplined customer support and technical execution. By Q4, they emphasized that, after a full fiscal year, the acquired portfolio would no longer be reported separately—signaling integration completion.
Quarter-by-quarter materiality and tone for annual transcript themes.
Scroll horizontally to see more columns.
| Theme | Q1 | Q2 | Q3 | Q4 | Next monitor |
|---|---|---|---|---|---|
| MFA integration embedded into Animal Health results | Positive Integrated MFA drove 55% Animal Health growth in Q1 | Positive Zoetis MFA execution and integration sustained strong gains |
Management’s annual narrative emphasized integrated portfolio momentum and initiative-driven profitability, but cash conversion remained pressured by inventory timing and regulatory uncertainty in Brazil.
Management linked early-quarter growth to integrating the acquired MFA portfolio, later stating it would no longer be separately reported after a full fiscal year—signaling embedding across Animal Health.
After initially describing Phibro Forward as a significant driver, management confirmed program conclusion in June and quantified expected cumulative EBITDA contributions reaching about $50 million in FY2027.
Management attributed margin improvements to strong mix (nutritional specialties and vaccines) and additional price, while also describing a smaller return-related elevation in Q2.
FY2026 began with integration-led acceleration, gained further momentum with margin and guidance raises in Q2, then balanced end-market/regulatory updates in Q3, ending with quantified transformation outcomes and prudently framed FY2027 guidance in Q4.
Improved profitability, limited free cash flow
Regional breakdown bars are scaled against the largest annual revenue item; labels show revenue, YoY change, and revenue share.
Q1 emphasized integration translating into Animal Health growth and an earnings guidance raise; Q2 broadened the story to margin drivers and cash pressure from inventory. Q3 added end-market and regulatory complexity. Q4 closed with quantified transformation outcomes and conservative FY2027 assumptions around Brazil.
Management positioned MFA integration and mix benefits as the core of Q1 performance, raising full-year earnings guidance while clarifying price impact was limited early and margins could soften later.
Read earnings transcriptWith strong top-line momentum, management raised FY2026 sales/EBITDA/income guidance and explained gross margin improvements via price, mix, and some return-related effects. At the same time, they disclosed inventory buildup ahead of tariffs pressured cash generation.
FY2026 guidance was updated multiple times and generally tracked management’s disclosed mix/expense and integration progress; some metrics were qualitative or partially measurable.
$1.425B to $1.475B (net sales); $225M to $235M (total adjusted EBITDA); $103M to $110M (adjusted net income) / midpoint EPS implied by guidance range
Revenue $1.52B; Other $255M; EPS $2.44
Q1’s revenue and adjusted EBITDA ranges were ultimately surpassed; management’s early integration/mix narrative appears to have translated into FY outcomes.
Key next-year monitoring points derived from repeated management explanations and Q&A themes.
It is the explicit known uncertainty shaping FY2027 revenue and especially EBITDA sensitivity.
Watch management’s regulatory timing commentary and whether any virginiamycin sales assumptions change versus “minimal contribution.”
Free cash flow remained limited in FY2026 and management tied it to inventory growth in the MFA portfolio.
Monitor Q1 working capital and inventory build disclosures; verify whether the FY2027 expected ~$25M-$30M remains on track.
Operating model & margin
In Q1, guidance updates emphasized benefits from Phibro Forward initiatives and mix/expense favorability. Q2 expanded on price, mix, and internal focus on higher-margin products. By Q4, management framed Phibro Forward as a completed 3-year program with embedded capabilities and quantified expected FY2027 EBITDA contribution.
Cash conversion & working capital
Management tied cash dynamics to inventory timing and builds: in Q2 they cited negative cash generation from inventory built ahead of tariffs and rising demand. Q3 and Q4 reiterated inventory buildup pressures, and Q4 specifically attributed limited free cash flow to an ~$86M inventory build in the newly acquired MFA portfolio.
Regulatory & geographic uncertainty
In Q3, management framed Brazil antimicrobials as nearing a regulatory transition culmination and described support for therapeutic registration progress. In Q4, they explicitly assumed minimal Brazil virginiamycin sales for planning and tied prudence in FY2027 guidance to potential timing slips and higher-margin EBITDA sensitivity.
Positive Diversified demand supported 13% Animal Health growth |
Positive Management ended separate reporting, signaling integration completion |
| Track whether legacy vs integrated Animal Health growth rates converge in FY2027 commentary. |
| Phibro Forward initiative increasingly reflected in margins | Positive Q1 guidance raised on initiative benefits and mix | Positive Management said Phibro Forward benefits accelerate toward FY2027 | Positive Program concluded; FY2027 cumulative EBITDA contribution quantified | Monitor gross margin drivers and the disclosed FY2027 Phibro Forward contribution narrative in Q1. |
| Inventory and working capital dynamics limited free cash flow | Negative Cash generation hurt by inventory build ahead of tariffs | Negative Inventory buildup again cited as drag on cash | Negative Q4 cited ~$86M inventory build in new MFA portfolio | Watch Q1 inventory trend and whether free cash flow conversion improves as FY2027 inventory build normalizes. |
| Brazil antimicrobials transition drove planning conservatism | Mixed Brazil regulatory transition described as culmination with transition period | Mixed FY2027 guidance assumes minimal virginiamycin sales in Brazil | Monitor management’s Brazil regulatory updates and any mention of virginiamycin therapeutic approvals in Q1. |
| Companion animal oral care innovations shifted from launch to reorders | Positive Restoris launched; management framed as companion oral care milestone | Positive Management reported VMX interest and continued companion animal excitement | Mixed Reorders improved; management tempered expectations on ROI yet | Track management’s companion animal reorders, Restoris reorder cadence, and any ROI commentary. |
| Gross margin improved via price, mix, and limited one-time factors | Positive Margin favorability driven by mix in vaccines and nutritional specialties | Positive Management attributed gross margin to price and mix plus returns | Neutral Higher gross profit from sales, partially offset by expense growth | Positive Gross margin credited to favorable mix and lower input costs | Monitor gross margin assumptions as management expects it to be essentially flat into FY2027. |
Across Q3 and Q4, management referenced differing end-market cycles (dairy/poultry/beef) and emphasized geographic reach as a way to manage through volatility and uncertainty.
Management repeatedly cited inventory buildup affecting cash generation, including negative impacts ahead of tariffs and a roughly $86 million inventory build tied to the newly acquired MFA portfolio.
Management assumed minimal Brazil virginiamycin sales in planning and framed potential timing slips (including election-related noise) as a source of upside/downside to FY2027.
Management described Restoris growth and reorders, but in Q4 also said expectations were tempered versus earlier plans due to limited success last fiscal year and this year.
Management discussed lumpy legacy MFA timing in Q2 and later described Zoetis MFA declines in Q4 as driven by difficult comparators rather than underlying deterioration.
Scroll horizontally to see more columns.
| Quarter | Revenue | YoY revenue growth | Diluted EPS | Gross margin | Investor read |
|---|---|---|---|---|---|
| Q1Sep-25 | $363.89M | -3.9% | $0.65 | 32.9% | Integration and mix lifted earnings; management cautioned margin and price dynamics would shift later in the year. |
| Q2Dec-25 | $373.91M | 2.8% | $0.67 | 35.5% | Guidance upside reflected margin drivers and expense leverage, but investors were warned inventory timing would weigh on cash. |
| Q3Mar-26 | $383.54M | 2.6% | $0.59 | 32.6% | The narrative shifted from only execution to also managing regulatory and end-market complexities through diversified reach. |
| Q4Jun-26 | $396.75M | 3.4% | $0.53 | 33.9% | Management closed the loop on transformation and set expectations for essentially flat gross margins with prudent regulatory assumptions. |
Management reported solid Animal Health growth despite complex protein and beef supply tightness, while discussing Brazil’s regulatory framework shift for antimicrobials and embedding Middle East risks into guidance assumptions.
Read earnings transcriptThe year-end call emphasized that integration is now embedded and Phibro Forward capabilities remain across the organization, while FY2027 guidance stayed prudent for virginiamycin Brazil uncertainty and acknowledged continued working-capital and SG&A run-rate effects.
Read earnings transcriptCapabilities are embedded now, and management quantified cumulative FY2027 EBITDA contribution reaching about $50M.
Track gross margin and EBITDA commentary for whether the program’s benefit pacing matches management’s FY2027 framing.
Management repeatedly highlighted that reported MFA growth can be lumpy due to timing and comparators.
Listen for legacy MFA timing updates and commentary on Zoetis MFA growth/outperformance into FY2027.
Management described reorders and ongoing evidence gathering, while also tempering ROI expectations.
Monitor Restoris reorder momentum and any quantified ROI or distributor traction metrics in companion animal updates.
Dafinchi